Masteron vs RAD-140
Moderate Research vs Emerging
monitor Mechanism-based · 46% Both Masteron and RAD-140 suppress the HPTA axis. Combined suppression deepens shutdown and extends recovery time. Plan PCT accordingly and monitor LH/FSH/testosterone.
Molecular Data
Masteron RAD-140
Weight 304.47 Da (base) 393.83 Da
Half-life ~2 days (propionate), ~10 days (enanthate) ~60 hours
Type DHT-derived anabolic steroid (C20H32O2) Nonsteroidal selective androgen receptor modulator (C20H16ClN5O2)
Key Benefits
Masteron
01 Produces a hard, dry, and grainy appearance by eliminating subcutaneous water retention
02 Mild anti-estrogenic properties that can reduce or replace the need for aromatase inhibitors on cycle
03 Does not aromatize, eliminating estrogen-mediated side effects from the compound itself
04 Enhances the visual effects of other steroids in a stack by reducing water retention and bloat
05 Modest increases in strength without significant weight gain, useful for weight-class athletes
06 Improves muscle density and vascularity at low body fat percentages
07 Well-tolerated with a relatively mild side effect profile compared to other anabolic steroids
08 Short detection window with propionate ester compared to many other injectable steroids
RAD-140
01 Potent anabolic activity in muscle tissue with high oral bioavailability
02 Tissue-selective action sparing the prostate and other androgen-sensitive organs
03 No aromatization to estrogen (no estrogen-related side effects such as water retention or gynecomastia)
04 No conversion to DHT (reduced risk of hair loss and prostate stimulation compared to testosterone)
05 Long half-life (~60 hours) permitting convenient once-daily oral dosing
06 Neuroprotective properties observed in preclinical models
07 Increased lean body mass and reduced fat mass in preclinical studies
Dosing Protocols
Masteron
300-500 mg/week / Every other day (propionate) or 2x per week (enanthate)
Cutting / Aesthetic Enhancement 300-400 mg/week Every other day (propionate) or 2x per week (enanthate)
Contest Preparation 400-500 mg/week Every other day or daily (propionate)
AI Replacement / Estrogen Management 200-300 mg/week Every other day (propionate) or 2x per week (enanthate)
RAD-140
10-20 mg/day / Once daily (oral)
Side Effects
Masteron
Hair loss and accelerated male pattern baldness (significant risk as a DHT derivative - the most commonly reported side effect)
Acne and increased skin oiliness, particularly on the back and shoulders
Suppression of natural testosterone production (requires PCT or ongoing TRT)
Injection site pain or discomfort (more common with propionate ester)
Mild aggression or irritability from elevated androgenic activity
HDL cholesterol suppression and adverse lipid profile changes
RAD-140
Testosterone suppression (dose-dependent, occurs in virtually all users by week 4-6)
Liver enzyme elevation (ALT, AST increases reported in clinical and anecdotal data)
Hair shedding (temporary, typically resolves after discontinuation)
Headaches (most common in the first 1-2 weeks, often transient)
Nausea (mild, usually with initial doses or on an empty stomach)
Lipid disruption (HDL suppression, LDL elevation)
Mild insomnia or sleep disturbance
Reduced libido and mood changes related to testosterone suppression
Contraindications
Prostate cancer (active or history of hormone-sensitive prostate cancer)
Breast cancer in males
Pregnancy or potential for pregnancy (causes virilization of female fetus)
Known hypersensitivity to drostanolone or any formulation components
Severe hepatic impairment
Pre-existing significant hair loss where further androgenic exposure is unacceptable
Polycythemia (hematocrit above 54% at baseline)
Uncontrolled cardiovascular disease or severe dyslipidemia
Pre-existing liver disease or elevated liver enzymes at baseline
Hormone-sensitive cancers (prostate cancer, certain breast cancers not being treated under clinical supervision)
Pregnancy or potential pregnancy (teratogenic risk from androgen receptor agonism)
Breastfeeding
Age under 25 (incomplete endocrine system maturation and higher risk of HPG axis disruption)
Concurrent use of hepatotoxic medications without medical supervision
Known cardiovascular disease (insufficient safety data for this population)
Research Evidence
Masteron RAD-140
Status Moderate Research Emerging
References 5 studies 5 studies
Latest March 2020 July 2020
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.